An Energy-Sustainable and Oxidative-Tolerant Nanofactory of Therapeutic Proteins for Long-Acting Therapy of Inflammatory Bowel Disease
ACS Nano · 18.08.2026 · 20 (32) · 22435-22451
DOI: 10.1021/acsnano.6c00379 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 08.08.2026. Verfasst von Qian Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, School of Pharmacy, Hangzhou Medical Co…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Nanostructures. Die Arbeit nennt 42 Literaturangaben. Gefördert von: HMC Seeking Truth Talent Project, National Natural Science Foundation of China (NSFC), Institutional Special Project of the Department of Science and Technology of Zhejiang Province.
Abstract (Originalsprache)
The ability to continuously generate bioactive therapeutics at the diseased site is an appealing and crucial advantage for the treatment of chronic relapsing diseases such as inflammatory bowel disease (IBD). Current in situ therapeutic factory strategies mainly rely on plasmid drugs, which are usually associated with poor stability and susceptibility to oxidative degradation in the inflammatory microenvironment. Furthermore, the transcription of plasmid-based drugs to produce therapeutic proteins is an energy-intensive process, whose energy demands are difficult to satisfy at inflammatory sites owing to the compromised oxygen availability and mitochondrial dysfunction. Inspired by a modern factory, where both energy supply and equipment maintenance are essential for continuous production, a nanozyme-augmented energy-sustainable and oxidative-tolerant nanofactory of therapeutic proteins (NENFpro) has been developed. NENFpro is constructed by integrating the pOTUD1 (plasmid encoding the anti-inflammatory deubiquitinase OTUD1) and biocatalytic iridium nanozyme (IrNZ) into the nanosized zeolitic imidazolate framework-8 (ZIF-8) scaffold. Benefiting from the excellent antioxidant capacity of the incorporated IrNZ, the structure and bioactivity of plasmid drugs are well maintained in the destructive inflammatory microenvironment with excessive reactive oxygen species (ROS). Moreover, IrNZ can catalytically generate oxygen and prevent mitochondrial damage, thereby supplying sufficient energy for the transcription process of plasmid-based drugs to produce anti-inflammatory OTUD1 for IBD treatment. This nanozyme-engineered nanofactory of therapeutic proteins represents a desirabl strategy for the in situ long-acting therapy of chronic IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang310053, China.
- State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, Zhejiang314102, China.
- Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Shanghai Advanced Research Institute, Sh…
ORCID-Profile: Daishun Ling, Haibin Wu
Förderung
- HMC Seeking Truth Talent Project
- National Natural Science Foundation of China (NSFC)
- Institutional Special Project of the Department of Science and Technology of Zhejiang Province
Zitieren
APA
Chen, Q., Xu, L., Duan, K., Song, F., Zhang, H., Huang, Z., Zheng, Z., Qiu, Y., Shi, S., Zhang, J., Xie, Y., Zeng, G., Zhang, Y., Yin, L., Ling, D., Liang, G., & Wu, H. (2026). An Energy-Sustainable and Oxidative-Tolerant Nanofactory of Therapeutic Proteins for Long-Acting Therapy of Inflammatory Bowel Disease. ACS Nano, 20(32), 22435-22451. https://doi.org/10.1021/acsnano.6c00379
Vancouver
Chen Q, Xu L, Duan K, Song F, Zhang H, Huang Z, et al. An Energy-Sustainable and Oxidative-Tolerant Nanofactory of Therapeutic Proteins for Long-Acting Therapy of Inflammatory Bowel Disease. ACS Nano. 2026;20(32):22435-22451. doi:10.1021/acsnano.6c00379
BibTeX
@article{Chen2026,
author = {Chen, Qian and Xu, Lenan and Duan, Ke and Song, Fengling and Zhang, Honglei and Huang, Ziyan and Zheng, Ziying and Qiu, Yi and Shi, Shuhan and Zhang, Jixiang and Xie, Yuting and Zeng, Guohuan and Zhang, Yawen and Yin, Lina and Ling, Daishun and Liang, Guang and Wu, Haibin},
title = {An Energy-Sustainable and Oxidative-Tolerant Nanofactory of Therapeutic Proteins for Long-Acting Therapy of Inflammatory Bowel Disease},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {32},
pages = {22435--22451},
doi = {10.1021/acsnano.6c00379}
}
EUVIMED